Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • Editorial Board
    • Meet the Editors
    • Editorial Manifesto
    • Impact Factor
    • Journal History
    • General Statistics
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • Circulation Research Profiles
    • Trainees & Young Investigators
    • Research Around the World
    • News & Views
    • The NHLBI Page
    • Viewpoints
    • Compendia
    • Reviews
    • Recent Review Series
    • Profiles in Cardiovascular Science
    • Leaders in Cardiovascular Science
    • Commentaries on Cutting Edge Science
    • AHA/BCVS Scientific Statements
    • Abstract Supplements
    • Circulation Research Classics
    • In This Issue Archive
    • Anthology of Images
  • Resources
    • Online Submission/Peer Review
    • Why Submit to Circulation Research
    • Instructions for Authors
    • → Article Types
    • → Manuscript Preparation
    • → Submission Tips
    • → Journal Policies
    • Circulation Research Awards
    • Image Gallery
    • Council on Basic Cardiovascular Sciences
    • Customer Service & Ordering Info
    • International Users
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Impact Factor 13.965
  • Facebook
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Circulation Research

  • My alerts
  • Sign In
  • Join

  • Impact Factor 13.965
  • Facebook
  • Twitter
  • Home
  • About this Journal
    • Editorial Board
    • Meet the Editors
    • Editorial Manifesto
    • Impact Factor
    • Journal History
    • General Statistics
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • Circulation Research Profiles
    • Trainees & Young Investigators
    • Research Around the World
    • News & Views
    • The NHLBI Page
    • Viewpoints
    • Compendia
    • Reviews
    • Recent Review Series
    • Profiles in Cardiovascular Science
    • Leaders in Cardiovascular Science
    • Commentaries on Cutting Edge Science
    • AHA/BCVS Scientific Statements
    • Abstract Supplements
    • Circulation Research Classics
    • In This Issue Archive
    • Anthology of Images
  • Resources
    • Online Submission/Peer Review
    • Why Submit to Circulation Research
    • Instructions for Authors
    • → Article Types
    • → Manuscript Preparation
    • → Submission Tips
    • → Journal Policies
    • Circulation Research Awards
    • Image Gallery
    • Council on Basic Cardiovascular Sciences
    • Customer Service & Ordering Info
    • International Users
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
Editorial

Not All Sudden Death Is the Same

P.D. Allen
Download PDF
https://doi.org/10.1161/01.RES.0000093184.27194.42
Circulation Research. 2003;93:484-486
Originally published September 18, 2003
P.D. Allen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Info & Metrics

Jump to

  • Article
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • eLetters
Loading
  • sudden death
  • sarcoplasmic reticulum
  • ryanodine receptors
  • ventricular tachycardia
  • FKBP12.6

Sudden death as a result of cardiac arrhythmia is probably the most common symptom associated with cardiac disease. It occurs not only in people with known cardiac disease, most notably congestive heart failure, but also in young, apparently healthy individuals who have no apparent structural heart disease. Frequently, in this latter group, these fatal arrhythmias are associated with exercise and increased β-adrenergic stimulation. One possible mechanism for how these arrhythmias could occur in otherwise “normal” individuals is an aberrant release of Ca2+ from the sarcoplasmic reticulum (SR), which in turn could cause delayed afterdepolarizations1 that can trigger potentially fatal ventricular arrhythmias.

Unlike skeletal muscle, where excitation-contraction coupling (EC coupling) is intermittent and mediated through a mechanical coupling between the slow voltage-gated Ca2+ channel (dihydropyridine receptor, DHPR) in the sarcolemma and the skeletal isoform of the large-conductance calcium release channel in the SR (ryanodine receptor, RyR), RyR1 in cardiac muscle EC coupling is rhythmic and the cardiac isoform of RyR (RyR2) is activated by the inward Ca2+ influx through the cardiac DHPR via Ca2+-induced Ca2+ release (CICR).2 In the heart, RyR2 does not act in a vacuum but rather is part of a macromolecular complex containing the immunophilin FKBP12.6, phosphorylases, and phosphatases,3 in addition to the DHPR and several other proteins including calsequestrin, triadin, junctin, and junctophilin, to name only a few, that make up the calcium release unit (CRU).4 Heart failure has been associated with disruption of this macromolecular complex secondary to hyperphosphorylation of RyR2 and the associated dissociation of FKBP12.6.5 Interestingly, mice that carry two null alleles for FKBP12.6 have been shown to have exercise- and catecholamine-induced fatal ventricular arrhythmias suggesting that this is a crucial subunit for controlling ventricular Ca2+ homeostasis.6

Recently, 11 missense mutations of RyR2 and one missense mutation of calsequestrin have been associated with a group of closely associated cardiomyopathies that are characterized by early sudden death: catecholaminergic polymorphic ventricular tachycardia (CPVT), arrhythmogenic right ventricular cardiomyopathy (ARVD2), and familial polymorphic ventricular tachycardia.7–10 Interestingly, the RyR2 mutations associated with these cardiomyopathies are clustered in the same hot spots as the more than 50 missense mutations in RyR1 that are associated with malignant hyperthermia (MH) and central core disease (CCD).11,12 Like CPVT and ARVD2, MH individuals have normal muscle histology and have a “normal” phenotype until triggered by exposure to a triggering agent or stress. MH mutations are associated with a high resting free myoplasmic Ca2+, increased sensitivity to caffeine and halothane, reduced internal Ca2+ stores, and a reduced sensitivity to Ca2+ and Mg2+ inhibition. This has led to the hypothesis that the cardiac RyR channelopathies are likely to result in an increased diastolic Ca2+, slowed relaxation after an action potential, and arrhythmogenic Ca2+ waves.

It has been previously shown by Jiang et al13 that, when studied in lipid bilayers, one CPVT RyR2 mutation (R4496C) expressed in HEK293 cells has an increased open probability at low (5 nmol/L) Ca2+ concentrations. However, at normal and elevated Ca2+ concentrations, there was no difference in the open probability between wt or mutant channel. Their findings, at Ca2+ concentrations above 150 nmol/L, were confirmed by Wehrens et al,6 who studied three CPVT mutations (S2246L, R2474S, and R4497C) expressed in the same heterologous cell line. In the latter study, it was demonstrated that the CPVD RyR2s were more sensitive to protein kinase A (PKA) phosphorylation, and it was suggested, based on an in vitro binding study, that CPVT RyR2s had a lower affinity for FKBP12.6. In this issue of Circulation Research, George et al14 report for the first time the effects that the expression of CPVT RyR2s have on cardiac cells. Using HL-I cardiomyocytes transfected with wt or three CPVT (S2246L, N4104K, and R4497C) RyR2 cDNAs, they overexpressed RyR2 by ≈2-fold. This did not suppress native wtRyR2 expression, and thus the mix of RyRs expressed mimics the clinical heterozygous situation. Interestingly, they demonstrated that in unstimulated cells, beating frequency was not increased in CPVT RyR2-expressing cultures; furthermore, the endoplasmic reticulum Ca2+ load was increased in all transfected cells, suggesting that, if CPVT RyR2s were leaky, there was a mechanism to completely compensate for such leakiness. As would be expected, they demonstrated that caffeine and 4-chloro-m-cresol (4CmC) sensitivity was shifted to the left in CPVT RyR2-expressing cells. They also showed that the Ca2+ release amplitude was higher and relaxation time was longer in these cells after exposure to these direct RyR agonists. They did not show a decrease in the amount of FKBP12.6 associated with the membrane fractions of these cells. This finding would have been predicted by Tiso et al15 from yeast two-hybrid studies but is the opposite of what has been suggested from studies of some of the same heterologously expressed CPVT RyR2s.6 They did find that CPVT RyR2-expressing cells were more sensitive to β-adrenergic receptor (β-AR) stimulation by either isoproterenol or forskolin and had prolonged Ca2+ transients under this circumstance, but this sensitivity was not due to differences either in the amount of RyR2 phosphorylation or the magnitude of the loss of FKBP12.6 from CPVT-expressing microsomes from what was seen for control cells or for cells overexpressing wtRyR2. It is certainly possible that the mechanism for their abnormal Ca2+ release after catecholamine stimulation is an increased sensitivity of CPVT RyR2s to PKA, as shown by Wehrens et al,6 but they clearly show that the mechanism for this increased sensitivity, if real, cannot simply be attributed to a lowered affinity for these CPVT RyR2s for FKBP12.6. At present, their findings strongly indicate that there must be an FKBP12.6-independent defect(s) in the regulation of CPVT RyR2s in HL-1 cardiomyocytes that leads to increased Ca2+ release on cell stimulation and the arrhythmias that could ensue. The precise nature of these defects remains to be defined.

The work of George et al14 is a critical step in understanding the mechanism by which these mutations in the RyR2 cause sudden death and shows the necessity of doing structure-function studies in appropriate cell lines or animal models. Currently, chronic administration of β-blockers is used in the management of CPVT, but due to the many intracellular targets of the β-AR signaling cascade, the results of their study indicate that precise in situ regulation of mutant RyR2 channel function represents an attractive and feasible therapeutic strategy. To develop novel therapeutic strategies in the management of CPVT/ARVD, it will be necessary to know the precise molecular mechanisms by which CPVT mutations in RyR2 cause the augmented Ca2+ release. The next step must be to develop an animal model(s) to facilitate studies of CPVT RyR structure function under normal physiological conditions and its regulation by Ca2+ and Mg2+. Attractive as a unifying hypothesis involving loss of FKBP12.6 might be for heart failure, CPVT, and ARVD,16 it is unlikely that all RyR2 channelopathies that cause sudden death have a common molecular mechanism leading to Ca2+ overload (Figure). Furthermore, similar cardiac phenotypes do not even have to be based on the same pathogenesis, as has been shown for patients with CPVT associated with the absence of cardiac calsequestrin rather than a mutation of RyR2.17

Figure1
  • Download figure
  • Open in new tab
  • Download powerpoint

a, During exercise- or catecholamine-induced stress, wtRyR2 releases more Ca2+, increasing myocardial contractility and an increased heart rate with a normal ECG. The proposed mechanism for this increase in Ca2+ release is partial dissociation of the FKBP12.6 from RyR2 due to phosphorylation of RyR2 by PKA. In arrhythmogenic disease states (b through d), the amount of Ca2+ release is greater, and this can lead to an elevated diastolic myoplasmic Ca2+. This elevation in myoplasmic Ca2+ can in turn lead to diastolic afterdepolarizations (DADs) that can initiate fatal ventricular tachyarrhythmias and cause sudden death. This increase in SR Ca2+ release can be mediated through a number of mechanisms. b, In FKBP12.6 knockout animals, chronic heart failure, where RyR2 is hyperphosphorylated, and possibly in the syndrome ARVD2, FKBP12.6 is either absent or completely dissociated from RyR2. c, In CPVT hearts, the amount of dissociation of FKBP12.6 is similar to control, but some other factor associated with the mutation in RyR2 increases SR Ca2+ release. d, In CPVT caused by the absence of cardiac calsequestrin, the phosphorylation state of RyR2 and the degree of dissociation of FKBP12.6 are unknown, but the phenotype is the same as b and c.

Footnotes

  • The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.

References

  1. ↵
    Fozzard HA. Afterdepolarizations and triggered activity. Basic Res Cardiol. 1992; 87 (suppl 2): 105–113.
    OpenUrlPubMed
  2. ↵
    Fabiato A. Calcium-induced release of calcium from the cardiac sarcoplasmic reticulum. Am J Physiol. 1983; 245: C1–C14.
    OpenUrlPubMed
  3. ↵
    Marx SO, Reiken S, Hisamatsu Y, Gaburjakova M, Gaburjakova J, Yang YM, Rosemblit N, Marks AR. Phosphorylation-dependent regulation of ryanodine receptors: a novel role for leucine/isoleucine zippers. J Cell Biol. 2001; 153: 699–708.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    Franzini-Armstrong C, Protasi F, Ramesh V. Shape, size, and distribution of Ca2+ release units and couplons in skeletal and cardiac muscles. Biophys J. 1999; 77: 1528–1539.
    OpenUrlCrossRefPubMed
  5. ↵
    Marks AR, Reiken S, Marx SO. Progression of heart failure: is protein kinase a hyperphosphorylation of the ryanodine receptor a contributing factor? Circulation. 2002; 105: 272–275.
    OpenUrlFREE Full Text
  6. ↵
    Wehrens XH, Lehnart SE, Huang F, Vest JA, Reiken SR, Mohler PJ, Sun J, Guatimosim S, Song LS, Rosemblit N, D’Armiento JM, Napolitano C, Memmi M, Priori SG, Lederer WJ, Marks AR. FKBP12.6 deficiency and defective calcium release channel (ryanodine receptor) function linked to exercise-induced sudden cardiac death. Cell. 2003; 113: 829–840.
    OpenUrlCrossRefPubMed
  7. ↵
    Priori SG, Napolitano C, Tiso N, Memmi M, Vignati G, Bloise R, Sorrentino VV, Danieli GA. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation. 2001; 103: 196–200.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    Priori SG, Napolitano C, Memmi M, Colombi B, Drago F, Gasparini M, DeSimone L, Coltorti F, Bloise R, Keegan R, Cruz Filho FE, Vignati G, Benatar A, DeLogu A. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation. 2002; 106: 69–74.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    Tiso N, Stephan DA, Nava A, Bagattin A, Devaney JM, Stanchi F, Larderet G, Brahmbhatt B, Brown K, Bauce B, Muriago M, Basso C, Thiene G, Danieli GA, Rampazzo A. Identification of mutations in the cardiac ryanodine receptor gene in families affected with arrhythmogenic right ventricular cardiomyopathy type 2 (ARVD2). Hum Mol Genet. 2001; 10: 189–194.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    Laitinen PJ, Brown KM, Piippo K, Swan H, Devaney JM, Brahmbhatt B, Donarum EA, Marino M, Tiso N, Viitasalo M, Toivonen L, Stephan DA, Kontula K. Mutations of the cardiac ryanodine receptor (RyR2) gene in familial polymorphic ventricular tachycardia. Circulation. 2001; 103: 485–490.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    Brandt A, Schleithoff L, Jurkat-Rott K, Klingler W, Baur C, Lehmann-Horn F. Screening of the ryanodine receptor gene in 105 malignant hyperthermia families: novel mutations and concordance with the in vitro contracture test. Hum Mol Genet. 1999; 8: 2055–2062.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    Loke J, MacLennan DH. Malignant hyperthermia and central core disease: disorders of Ca2+ release channels. Am J Med. 1998; 104: 470–86.
    OpenUrlCrossRefPubMed
  13. ↵
    Jiang D, Xiao B, Zhang L, Chen SR. Enhanced basal activity of a cardiac Ca2+ release channel (ryanodine receptor) mutant associated with ventricular tachycardia and sudden death. Circ Res. 2002; 91: 218–225.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    George CH, Higgs GV, Lai FA. Ryanodine receptor mutations associated with stress-induced ventricular tachycardia mediate increased calcium release in stimulated cardiomyocytes. Circ Res. 2003; 93: 531–540.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    Tiso N, Salamon M, Bagattin A, Danieli GA, Argenton F, Bortolussi M. The binding of the RyR2 calcium channel to its gating protein FKBP12.6 is oppositely affected by ARVD2 and VTSIP mutations. Biochem Biophys Res Commun. 2002; 299: 594–598.
    OpenUrlCrossRefPubMed
  16. ↵
    Most P, Koch WJ. Sealing the leak, healing the heart. Nat Med. 2003; 9: 993–994.
    OpenUrlCrossRefPubMed
  17. ↵
    Postma AV, Denjoy I, Hoorntje TM, Lupoglazoff JM, Da Costa A, Sebillon P, Mannens MM, Wilde AA, Guicheney P. Absence of calsequestrin 2 causes severe forms of catecholaminergic polymorphic ventricular tachycardia. Circ Res. 2002; 91: 21–26.
    OpenUrlCrossRef
View Abstract
Back to top
Previous ArticleNext Article

This Issue

Circulation Research
September 19, 2003, Volume 93, Issue 6
  • Table of Contents
Previous ArticleNext Article

Jump to

  • Article
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics

Article Tools

  • Print
  • Citation Tools
    Not All Sudden Death Is the Same
    P.D. Allen
    Circulation Research. 2003;93:484-486, originally published September 18, 2003
    https://doi.org/10.1161/01.RES.0000093184.27194.42

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  •  Download Powerpoint
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Circulation Research.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Not All Sudden Death Is the Same
    (Your Name) has sent you a message from Circulation Research
    (Your Name) thought you would like to see the Circulation Research web site.
  • Share on Social Media
    Not All Sudden Death Is the Same
    P.D. Allen
    Circulation Research. 2003;93:484-486, originally published September 18, 2003
    https://doi.org/10.1161/01.RES.0000093184.27194.42
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Subjects

  • Basic, Translational, and Clinical Research
    • Cell Signaling/Signal Transduction
    • Calcium Cycling/Excitation-Contraction Coupling
  • Arrhythmia and Electrophysiology
    • Arrhythmias

Circulation Research

  • About Circulation Research
  • Editorial Board
  • Instructions for Authors
  • Abstract Supplements
  • AHA Statements and Guidelines
  • Permissions
  • Reprints
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Editorial Office Address:
3355 Keswick Rd
Main Bldg 103
Baltimore, MD 21211
CircRes@circresearch.org

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured